Demographic and treatment characteristics of patients
| . | BMT . | PBSCT . | CD34-PBSCT . | P CD34-PBSCT versus BMT/ CD34-PBSCT versus PBSCT . |
|---|---|---|---|---|
| No. of patients | 22 | 19 | 32 | |
| Median age (range, y) | ||||
| Patients | 38 (18-59) | 39 (16-53) | 37 (22-57) | NS/NS |
| Donors | 41 (12-65) | 42 (18-63) | 36 (18-61) | NS/NS |
| Sex, no.(%) | ||||
| Male, with male donor | 2 (9) | 4 (21) | 10 (31) | < .01/NS |
| Male, with female donor | 8 (36) | 5 (26) | 9 (28) | NS |
| Female, with female donor | 3 (14) | 5 (26) | 6 (19) | NS |
| Female, with male donor | 9 (41) | 5 (26) | 7 (22) | NS |
| Median time interval (range) between diagnosis and transplantation (mos) | 14 (6-23) | 12 (4-148) | 10 (3-29) | < .09/NS |
| Median graft size (range) | ||||
| Nucleated cell dose (× 108/kg) | 3.1 (1.58-5.0) | 9.1 (4.4-29.6) | — | — |
| CD34+ cell dose (× 106/kg) | 3.4 (1.5-6.8) | 8.0 (3.4-26.0) | 7.8 (4.7-17.0) | .001/NS |
| GVHD prophylaxis, no. | ||||
| Short methotrexate and cyclosporine A | 21 | 19 | 1 | — |
| No GVHD prophylaxis | 0 | 0 | 31 | — |
| Myeloablative regimen, no. (%) | ||||
| TBI and cyclophosphamide | 21 (95) | 18 (95) | 1 (3) | — |
| Busulfan and cyclophosphamide | 1 (5) | 1 (3) | 0 | — |
| TBI, cyclophosphamide, thiotepa, ATG | 0 | 0 | 26 (81) | — |
| TBI, cyclophosphamide, thiotepa | 0 | 0 | 5 (16) | — |
| Cytomegalovirus status, no. (%) | ||||
| Seropositive, with seropositive donor | 12 (55) | 10 (53) | 11 (33) | NS/NS |
| Seropositive, with seronegative donor | 1 (5) | 1 (5) | 4 (12) | NS/NS |
| Seronegative, with seronegative donor | 6 (27) | 5 (26) | 12 (39) | NS/NS |
| Seronegative, with seropositive donor | 3 (14) | 3 (16) | 5 (15) | NS/NS |
| Patients receiving G-CSF (%) | 4 (8%) | 2 (6%) | 24 (75) | < .01/< .01 |
| Median follow-up (range, mos) | 20 (4-48) | 18 (4-40) | 18 (2-40) | NS/NS |
| . | BMT . | PBSCT . | CD34-PBSCT . | P CD34-PBSCT versus BMT/ CD34-PBSCT versus PBSCT . |
|---|---|---|---|---|
| No. of patients | 22 | 19 | 32 | |
| Median age (range, y) | ||||
| Patients | 38 (18-59) | 39 (16-53) | 37 (22-57) | NS/NS |
| Donors | 41 (12-65) | 42 (18-63) | 36 (18-61) | NS/NS |
| Sex, no.(%) | ||||
| Male, with male donor | 2 (9) | 4 (21) | 10 (31) | < .01/NS |
| Male, with female donor | 8 (36) | 5 (26) | 9 (28) | NS |
| Female, with female donor | 3 (14) | 5 (26) | 6 (19) | NS |
| Female, with male donor | 9 (41) | 5 (26) | 7 (22) | NS |
| Median time interval (range) between diagnosis and transplantation (mos) | 14 (6-23) | 12 (4-148) | 10 (3-29) | < .09/NS |
| Median graft size (range) | ||||
| Nucleated cell dose (× 108/kg) | 3.1 (1.58-5.0) | 9.1 (4.4-29.6) | — | — |
| CD34+ cell dose (× 106/kg) | 3.4 (1.5-6.8) | 8.0 (3.4-26.0) | 7.8 (4.7-17.0) | .001/NS |
| GVHD prophylaxis, no. | ||||
| Short methotrexate and cyclosporine A | 21 | 19 | 1 | — |
| No GVHD prophylaxis | 0 | 0 | 31 | — |
| Myeloablative regimen, no. (%) | ||||
| TBI and cyclophosphamide | 21 (95) | 18 (95) | 1 (3) | — |
| Busulfan and cyclophosphamide | 1 (5) | 1 (3) | 0 | — |
| TBI, cyclophosphamide, thiotepa, ATG | 0 | 0 | 26 (81) | — |
| TBI, cyclophosphamide, thiotepa | 0 | 0 | 5 (16) | — |
| Cytomegalovirus status, no. (%) | ||||
| Seropositive, with seropositive donor | 12 (55) | 10 (53) | 11 (33) | NS/NS |
| Seropositive, with seronegative donor | 1 (5) | 1 (5) | 4 (12) | NS/NS |
| Seronegative, with seronegative donor | 6 (27) | 5 (26) | 12 (39) | NS/NS |
| Seronegative, with seropositive donor | 3 (14) | 3 (16) | 5 (15) | NS/NS |
| Patients receiving G-CSF (%) | 4 (8%) | 2 (6%) | 24 (75) | < .01/< .01 |
| Median follow-up (range, mos) | 20 (4-48) | 18 (4-40) | 18 (2-40) | NS/NS |
Significances were tested by comparing CD34+-PBSCT versus BMT and CD34+-PBSCT versus PBSCT.
NS indicates not significant; —, significant calculations not done.